Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Bimekizumab Promising for PsA

Michele B. Kaufman, PharmD, BCGP  |  December 18, 2018

CHICAGO—Bimekizumab is an investigational interleukin (IL) 17A and IL-17 neutralizing agent being studied to modulate inflammation in psoriasis, psoriatic arthritis and ankylosing spondylitis. During the late-breaking abstract session at the 2018 ACR/ARHP Annual Meeting, researchers reported on the results of a 48-week, Phase 2b, randomized, double-blind, placebo-controlled study of bimekizumab in patients with active psoriatic arthritis (PsA).1

In the study, 206 patients with active PsA were randomized into five groups to receive either 16 mg bimekizumab, 160 mg bimekizumab, 160 mg bimekizumab with a 320 mg bimekizumab loading dose, 320 mg bimekizumab or placebo every four weeks for 12 weeks. The study’s primary endpoint was the ACR50 response at Week 12.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At baseline, patients had to have a swollen joint count of at least three out of 76, a tender joint count of three out of 78 and fulfill the CASPAR criteria. Nineteen percent of patients had prior exposure to tumor necrosis factor-alpha inhibitors.

After Week 12, placebo-treated patients and 16 mg bimekizumab-treated patients were re-randomized to receive 160 mg or 320 mg bimekizumab. All other patients remained on their previous doses.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
More than 91% of patients completed the double-blind and dose-blind periods, with demographics and baseline disease characteristics balanced across groups.

At Week 12, patients showed a statistically significant dose response for ACR50. Additionally, significantly more bimekizumab-treated patients than placebo-treated patients achieved ACR20, ACR50 and PASI90 (in patients with a body surface area of at least 3% at baseline). Patients who continued their initial bimekizumab dose had increased response rates up to Week 24 for ACR 20, ACR50, ACR70, PASI75, PASI90, MDA and enthesitis resolution. These responses were sustained throughout the study and were comparable across the three highest dosed groups at Week 48.

Treatment-emergent adverse events showed no apparent dose relationship. Serious adverse events were seen in 4.4% of patients up to Week 48. The most common adverse event was nasopharyngitis, occurring in 12.1% of patients. Oral candidiasis was also reported in 4.9% of bimekizumab-treated patients. No cases of inflammatory bowel disease, major adverse cardiac events or death were reported.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. Ritchlin CT, Kavanaugh A, Merola JF, et al. Dual neutralization of IL-17A and IL-17F with bimekizumab in patients with active PsA: Results from a 48-week phase 2b, randomized, double‑blind, placebo-controlled, dose-ranging study [abstract]. Arthritis Rheumatol. 2018 Oct; 70(suppl 10).

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:BimekizumabPsoriatic Arthritis

Related Articles

    Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

    December 1, 2022

    PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

    Ankylosing Spondylitis Patients Report Improved Quality of Life with Bimekizumab

    July 8, 2019

    Recent research shows bimekizumab may improve patient-reported outcomes and quality of life for ankylosing spondylitis (AS) patients…

    Bimekizumab Improves Joint & Skin Symptoms in PsA Patients

    January 16, 2018

    Preliminary results from an ongoing study show that bimekizumab improves joint and skin symptoms in patients with psoriatic arthritis…

    Never Too Late: Late-Breaking Abstracts Create Excitement

    July 15, 2022

    EULAR 2022 (VIRTUAL)—The pace of scientific progress in research medicine is incredible and seems to only accelerate with time. Thus, the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR) session on late-breaking abstracts fittingly captured the excitement and timeliness of a number of research projects that have just recently been completed and…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences